BTIG lowered the firm’s price target on Privia Health to $30 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 earnings in Health Tech. The analyst states that heading into the quarter, the firm sees hospital cap-ex and buying cycle to improve, with better inflation trends and volumes. The firm is also expecting a slight uptick in procedure volumes and continued demand for value-based-care solutions, along with some impact from obesity management. BTIG is cutting its price target on the stock due to the macro pullback but notes that the company should benefit from good ambulatory volumes and increased demand for value-based-care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRVA:
- Privia Health price target lowered to $26 from $32 at Evercore ISI
- Privia Health to Report Third Quarter 2023 Results on Friday, November 3
- Privia Health to leverage Navina’s AI platform to improve physician workflow
- Privia Health to Participate in the Morgan Stanley Healthcare Conference
- Privia Health says ACOs achieved shared savings of $131.7M through MSSP